AORT vs. ATRC, MDXG, FNA, KIDS, SILK, ATRI, TMCI, SIBN, EMBC, and IRMD
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include AtriCure (ATRC), MiMedx Group (MDXG), Paragon 28 (FNA), OrthoPediatrics (KIDS), Silk Road Medical (SILK), Atrion (ATRI), Treace Medical Concepts (TMCI), SI-BONE (SIBN), Embecta (EMBC), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
Artivion (NYSE:AORT) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
AtriCure received 533 more outperform votes than Artivion when rated by MarketBeat users. However, 70.00% of users gave Artivion an outperform vote while only 68.98% of users gave AtriCure an outperform vote.
In the previous week, Artivion had 16 more articles in the media than AtriCure. MarketBeat recorded 22 mentions for Artivion and 6 mentions for AtriCure. Artivion's average media sentiment score of 0.64 beat AtriCure's score of 0.64 indicating that Artivion is being referred to more favorably in the media.
Artivion presently has a consensus price target of $27.50, suggesting a potential upside of 16.87%. AtriCure has a consensus price target of $49.78, suggesting a potential upside of 123.22%. Given AtriCure's higher probable upside, analysts clearly believe AtriCure is more favorable than Artivion.
Artivion has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 8.1% of Artivion shares are owned by company insiders. Comparatively, 3.2% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Artivion has a net margin of -2.61% compared to AtriCure's net margin of -8.98%. Artivion's return on equity of 3.64% beat AtriCure's return on equity.
AtriCure has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.
Summary
Artivion beats AtriCure on 10 of the 17 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artivion Competitors List
Related Companies and Tools
